The Risks, Benefits, and Uncertainties of Stepping Down Asthma Medications

Matthew A Rank, Stephen P. Peters

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Stepwise adjustments have been suggested as a framework to manage chronic asthma over time. In this framework, individuals with good asthma control and a low risk for future asthma exacerbations may be considered for a reduction or "step down" of their chronic asthma medications. In this article, we discuss how patients may benefit or be harmed by stepping down asthma medications. Based on the literature presented in this article, we recommend that clinicians discuss the option of stepping down with patients when symptoms are stable, lung function is near normal, and biomarkers (if measured) are near normal. Other factors that should be considered in the decision to step down include the length of asthma stability, age of the patient, time of year, and patient preferences. Reducing the dose of inhaled corticosteroid by 25% to 50% appears to be the safest method of stepping down. A clear plan of care and follow-up is needed when stepping down asthma medications because many patients are likely to have recurrent exacerbations.

Original languageEnglish (US)
Pages (from-to)503-509
Number of pages7
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume2
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Uncertainty
Asthma
Aftercare
Patient Preference
Adrenal Cortex Hormones
Biomarkers
Lung

Keywords

  • Anti-asthmatic agents
  • Asthma
  • Cessation
  • Decrease
  • Discontinue
  • Step down
  • Wean
  • Withdraw

ASJC Scopus subject areas

  • Immunology and Allergy
  • Medicine(all)

Cite this

The Risks, Benefits, and Uncertainties of Stepping Down Asthma Medications. / Rank, Matthew A; Peters, Stephen P.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 2, No. 5, 2014, p. 503-509.

Research output: Contribution to journalArticle

@article{d4f2331c88124e69900fdf0fbf9b795b,
title = "The Risks, Benefits, and Uncertainties of Stepping Down Asthma Medications",
abstract = "Stepwise adjustments have been suggested as a framework to manage chronic asthma over time. In this framework, individuals with good asthma control and a low risk for future asthma exacerbations may be considered for a reduction or {"}step down{"} of their chronic asthma medications. In this article, we discuss how patients may benefit or be harmed by stepping down asthma medications. Based on the literature presented in this article, we recommend that clinicians discuss the option of stepping down with patients when symptoms are stable, lung function is near normal, and biomarkers (if measured) are near normal. Other factors that should be considered in the decision to step down include the length of asthma stability, age of the patient, time of year, and patient preferences. Reducing the dose of inhaled corticosteroid by 25{\%} to 50{\%} appears to be the safest method of stepping down. A clear plan of care and follow-up is needed when stepping down asthma medications because many patients are likely to have recurrent exacerbations.",
keywords = "Anti-asthmatic agents, Asthma, Cessation, Decrease, Discontinue, Step down, Wean, Withdraw",
author = "Rank, {Matthew A} and Peters, {Stephen P.}",
year = "2014",
doi = "10.1016/j.jaip.2014.03.004",
language = "English (US)",
volume = "2",
pages = "503--509",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The Risks, Benefits, and Uncertainties of Stepping Down Asthma Medications

AU - Rank, Matthew A

AU - Peters, Stephen P.

PY - 2014

Y1 - 2014

N2 - Stepwise adjustments have been suggested as a framework to manage chronic asthma over time. In this framework, individuals with good asthma control and a low risk for future asthma exacerbations may be considered for a reduction or "step down" of their chronic asthma medications. In this article, we discuss how patients may benefit or be harmed by stepping down asthma medications. Based on the literature presented in this article, we recommend that clinicians discuss the option of stepping down with patients when symptoms are stable, lung function is near normal, and biomarkers (if measured) are near normal. Other factors that should be considered in the decision to step down include the length of asthma stability, age of the patient, time of year, and patient preferences. Reducing the dose of inhaled corticosteroid by 25% to 50% appears to be the safest method of stepping down. A clear plan of care and follow-up is needed when stepping down asthma medications because many patients are likely to have recurrent exacerbations.

AB - Stepwise adjustments have been suggested as a framework to manage chronic asthma over time. In this framework, individuals with good asthma control and a low risk for future asthma exacerbations may be considered for a reduction or "step down" of their chronic asthma medications. In this article, we discuss how patients may benefit or be harmed by stepping down asthma medications. Based on the literature presented in this article, we recommend that clinicians discuss the option of stepping down with patients when symptoms are stable, lung function is near normal, and biomarkers (if measured) are near normal. Other factors that should be considered in the decision to step down include the length of asthma stability, age of the patient, time of year, and patient preferences. Reducing the dose of inhaled corticosteroid by 25% to 50% appears to be the safest method of stepping down. A clear plan of care and follow-up is needed when stepping down asthma medications because many patients are likely to have recurrent exacerbations.

KW - Anti-asthmatic agents

KW - Asthma

KW - Cessation

KW - Decrease

KW - Discontinue

KW - Step down

KW - Wean

KW - Withdraw

UR - http://www.scopus.com/inward/record.url?scp=84918832074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918832074&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2014.03.004

DO - 10.1016/j.jaip.2014.03.004

M3 - Article

C2 - 25213042

AN - SCOPUS:84918832074

VL - 2

SP - 503

EP - 509

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 5

ER -